Sunday |
4:00 pm - 8:00 pm | Arrival and Check-in |
6:00 pm | Dinner |
7:30 pm - 7:40 pm | Welcome / Introductory Comments by GRC Site Staff |
7:40 pm - 9:30 pm | Keynote Session: The Role of Government in Enabling New Antibacterial Discovery and Development |
| Discussion Leaders: Heike Broetz-Oesterhelt (Institute for Microbiology and Infection Medicine, University of Tübingen, Germany) and Jennifer Leeds (Novartis Institutes for BioMedical Research, USA) |
7:40 pm - 7:55 pm | Opening Remarks |
7:55 pm - 8:00 pm | Introduction by Discussion Leader |
8:00 pm - 8:35 pm | Sally Davies (U.K. Department of Health, United Kingdom) "Global Policy in Antimicrobial Resistance (AMR)" |
8:35 pm - 8:45 pm | Discussion |
8:45 pm - 9:20 pm | Sumathi Nambiar (U.S. Food and Drug Administration, USA) "FDA Perspective on Antibacterial Drug Development" |
9:20 pm - 9:30 pm | Discussion |
Monday |
7:30 am - 8:30 am | Breakfast |
9:00 am - 12:30 pm | New Antibacterial Targets: Focusing on Likelihood of Success |
| This session will focus on which new targets deserve our attention, and why are they more likely to enable successful drugs. |
| Discussion Leader: Hans-Georg Sahl (University of Bonn, Germany) |
9:00 am - 9:05 am | Introduction by Discussion Leader |
9:05 am - 9:40 am | Sarah McLeod (Entasis Therapeutics, USA) "Small Molecule Inhibitors of Gram-Negative Lipoprotein Trafficking Discovered by Phenotypic Screening" |
9:40 am - 9:50 am | Discussion |
9:50 am - 10:25 am | Tanja Schneider (University of Bonn, Germany) "Targeting Bactoprenol-Bound Cell Envelope Precursors" |
10:25 am - 10:35 am | Discussion |
10:35 am - 11:00 am | Coffee Break |
11:00 am - 11:35 am | Sarah Ades (Pennsylvania State University, USA) "Targeting Stress: Identifying Inhibitors of SigmaE-Hfq-sRNA Virulence Pathway" |
11:35 am - 11:45 am | Discussion |
11:45 am - 12:20 pm | Rolf Mueller (Helmholtz-Institute for Pharmaceutical Research Saarland, Germany) "Natural Product Research Towards Innovative Antibacterial Target-Compound Pairs: Challenges and Opportunities" |
12:20 pm - 12:30 pm | Discussion |
12:30 pm | Lunch |
1:30 pm - 4:30 pm | Free Time |
3:00 pm - 4:00 pm | Power Hour |
| The GRC Power Hour is an optional informal gathering open to all meeting participants. It is designed to help address the challenges women face in science and support the professional growth of women in our communities by providing an open forum for discussion and mentoring. |
| Organizers: Aileen Rubio (Spero Therapeutics, USA) and Nienke Buddelmeijer (Institut Pasteur, France) |
4:30 pm - 6:00 pm | Poster Session |
6:00 pm - 8:00 pm | Technologies to Enable Antibacterial Discovery and Development |
| This session will focus on what technologies are necessary to bring new compounds against novel targets to the clinic, and where are the innovative approaches to doing so. |
| Discussion Leader: Terry Roemer (Merck Infectious Disease Research, USA) |
6:00 pm - 6:05 pm | Introduction by Discussion Leader |
6:05 pm - 6:30 pm | Domingo Gargallo-Viola (ABAC Therapeutics, Spain) "Use of the PasNas Platform to Enable High Quality Antibacterial Hit Finding" |
6:30 pm - 6:40 pm | Discussion |
6:40 pm - 7:10 pm | Mariana Pinho (Instituto de Tecnologia Quimica e Biologica, Portugal) "Studying Antibiotic Mechanisms of Action at the Single Cell Level" |
7:10 pm - 7:20 pm | Discussion |
7:20 pm - 7:50 pm | Joe Pogliano (University of California, San Diego, USA) "Bacterial Cytological Profiling: A New Platform for Antibiotic Discovery" |
7:50 pm - 8:00 pm | Discussion |
8:00 pm | Dinner |
Tuesday |
7:30 am - 8:30 am | Breakfast |
8:30 am | Group Photo |
9:00 am - 12:30 pm | Identifying High-Value Chemical Starting Points: Hit Finding Revisited |
| This session will focus on what defines a high value chemical starting point and where do those come from. Speakers will offer detailed examples to demonstrate how these have enabled/will enable antibacterial drug discovery. |
| Discussion Leader: Michael Barbachyn (Calvin College, USA) |
9:00 am - 9:05 am | Introduction by Discussion Leader |
9:05 am - 9:35 am | Folkert Reck (Novartis Institutes for Biomedical Research, USA) "Chemical Property Space – Considerations for Antibacterial Drug Discovery" |
9:35 am - 9:45 am | Discussion |
9:45 am - 10:15 am | Christina Spry (The Australian National University, Australia) "Fragment-Based Approaches to Antibacterial Lead Discovery: Targeting Coenzyme A Biosynthesis in Mycobacterium tuberculosis" |
10:15 am - 10:25 am | Discussion |
10:25 am - 10:55 am | Coffee Break |
10:55 am - 11:25 am | Olga Genilloud (Fundación MEDINA, Spain) "Discovering High Value Hits from Microbial Natural Products" |
11:25 am - 11:35 am | Discussion |
11:35 am - 12:05 pm | Matthew Cooper (The University of Queensland, Australia) "Chemical Diversity in Screening Libraries for Antibiotic Action: Academic Collections vs. Commercial Libraries" |
12:05 pm - 12:15 pm | Discussion |
12:15 pm - 12:25 pm | Bradley Poulsen (Massachussetts General Hospital / Broad Institute, Harvard Medical School, USA) "A Multiplexed Chemical Screen of Pseudomonas aeruginosa Hypomorphs Rapidly Identifies Novel Antibiotic Leads" |
12:25 pm - 12:30 pm | Discussion |
12:30 pm | Lunch |
1:30 pm - 4:30 pm | Free Time |
4:30 pm - 6:00 pm | Poster Session |
6:00 pm - 8:00 pm | Addressing the Gap Between In Vitro (Target) and In Vivo (Cellular) Potency: Strategies to Enable the Latter |
| This session will focus on strategies to narrow the gap between target and cellular potency, which is a particular challenge in certain types of bacteria such as Gram negatives and TB. |
| Discussion Leader: Charles Dean (Novartis Intitutes for Biomedical Research, USA) |
6:00 pm - 6:05 pm | Introduction by Discussion Leader |
6:05 pm - 6:35 pm | Athanasios Typas (European Molecular Biology Laboratory, Germany) "Combinatorial Drug Treatments: From Drug Repurposing to Discovering General Design Principles and Underlying Mechanisms" |
6:35 pm - 6:45 pm | Discussion |
6:45 pm - 7:10 pm | Paolo Ruggerone (University of Cagliari, Italy) "Membrane Barrier in Drug Resistance: Microscopic Insights into Influx and Efflux Combinations" |
7:10 pm - 7:20 pm | Discussion |
7:20 pm - 7:50 pm | Olga Lomovskaya (The Medicines Company, USA) "Discovery of Novel Broad-Spectrum Carbapenemase Inhibitors: Challenges and Opportunities" |
7:50 pm - 8:00 pm | Discussion |
8:00 pm | Dinner |
Wednesday |
7:30 am - 8:30 am | Breakfast |
9:00 am - 12:30 pm | Learning from Clinical Experience with Validated Targets |
| This session will focus on the challenges and opportunities associated with drugs against clinically-precedented antibacterial targets. Examples will provide a learning experience for the community. |
| Discussion Leader: Michael Dudley (The Medicines Company, USA) |
9:00 am - 9:05 am | Introduction by Discussion Leader |
9:05 am - 9:40 am | Seamus O'Brien (AstraZeneca, United Kingdom) "Envisioning the Path from Idea to Registration: Lessons from Recent Antibacterial Development Programs" |
9:40 am - 9:50 am | Discussion |
9:50 am - 10:25 am | Mary Motyl (Merck Sharp & Dohme Corp., USA) "Learnings from Planning a Phase 3 Trial of Imipenem/Relebactam Against Imipenem-Resistant Gram Negative Rods" |
10:25 am - 10:35 am | Discussion |
10:35 am - 11:05 am | Coffee Break |
11:05 am - 11:40 am | Jacques Dumas (Tetraphase Pharmaceuticals, Inc., USA) "Learnings from Planning Global Trials with Eravacycline" |
11:40 am - 11:50 am | Discussion |
11:50 am - 12:20 pm | Daniel Ritz (Actelion Pharmaceuticals Ltd, Switzerland) "Unique Aspects of Cadezolid, a Novel Quinolonyl-Oxazolidinone in Development for Treatment of C. difficile Infections" |
12:20 pm - 12:30 pm | Discussion |
12:30 pm | Lunch |
1:30 pm - 4:30 pm | Free Time |
4:30 pm - 6:00 pm | Poster Session |
6:00 pm - 8:00 pm | Learning from Clinical Experience with Novel Targets |
| This session will focus on the challenges and opportunities associated
with drugs against clinically-unprecedented antibacterial targets. Examples
will provide a learning experience for the community. |
| Discussion Leader: Ursula Theuretzbacher (Center for Anti-Infective Agents, Austria) |
6:00 pm - 6:05 pm | Introduction by Discussion Leader |
6:05 pm - 6:35 pm | Antonio DiGiandomenico (MedImmune, LLC, USA) "MEDI3902: A Novel Multi-Mechanistic Bispecific
Antibody for Prevention of Pneumonia in Ventilated Patients Caused by Pseudomonas
aeruginosa" |
6:35 pm - 6:45 pm | Discussion |
6:45 pm - 7:10 pm | Frederick Wittke (Debiopharm International SA, Switzerland) "Debi0 1450: A New Antimicrobial Agent Specifically Targeting Complicated Staphylococcal Infections" |
7:10 pm - 7:20 pm | Discussion |
7:20 pm - 7:50 pm | Roger Echols (Shionogi Inc., USA) "Stumbling Towards Approval of a Pathogen-Focused Antibiotic: The Story of S-649266, a Siderophore Cephalosporin" |
7:50 pm - 8:00 pm | Discussion |
8:00 pm | Dinner |
Thursday |
7:30 am - 8:30 am | Breakfast |
8:30 am - 9:00 am | Business Meeting |
| Nominations for the Next Vice Chair; Fill in Conference Evaluation Forms; Discuss Future Site and Scheduling Preferences; Election of the Next Vice Chair |
9:00 am - 12:30 pm | Alternative Mechanisms of Action and Antibacterial Modalities |
| This session will focus on non-traditional approaches to antibacterial drugs, including novel combination approaches. |
| Discussion Leader: Robert Hancock (University of British Columbia, Canada) |
9:00 am - 9:05 am | Introduction by Discussion Leader |
9:05 am - 9:40 am | Man-Wah Tan (Genentech Inc, USA) "Antibody-Antibiotic Conjugate for Treatment of Bacterial Infections" |
9:40 am - 9:50 am | Discussion |
9:50 am - 10:25 am | Cristina Landeta (Harvard Medical School, USA) "Targeting Disulfide Bond Formation in Bacteria" |
10:25 am - 10:35 am | Discussion |
10:35 am - 11:00 am | Coffee Break |
11:00 am - 11:35 am | Aileen Rubio (Spero Therapeutics, USA) "Disarming P. aeruginosa Through Inhibition of MvfR" |
11:35 am - 11:45 am | Discussion |
11:45 am - 11:55 am | Selected from Poster Abstracts: Mark Broenstrup (Helmholtz Centre for Infection Research, Germany) "Induction and Quantification of Small Molecule Uptake into Gram-Negative Bacteria" |
11:55 am - 12:00 pm | Discussion |
12:00 pm - 12:10 pm | Selected from Poster Abstracts: Renee Bouley (University of Notre Dame, USA) "Exploration of the Mechanism of Action and Structure-Activity Relationship for a New Class of Quinazolinone Antibiotics" |
12:10 pm - 12:15 pm | Discussion |
12:15 pm - 12:30 pm | Poster Previews |
12:30 pm | Lunch |
1:30 pm - 4:30 pm | Free Time |
4:30 pm - 6:00 pm | Poster Session |
6:00 pm - 8:00 pm | The Future of Antibacterial Diagnostics: How Will New Diagnostics Enable Clinical Trial Design and Clinical Use of New Antibacterials? |
| Discussion Leader: Herman Goossens (University Hospital Antwerp, Belgium) |
6:00 pm - 6:05 pm | Introduction by Discussion Leader |
6:05 pm - 6:35 pm | Linda Miller (GlaxoSmithKline, USA) "Precision Medicine and Diagnostics: Trade-Offs, Challenges, and Opportunities" |
6:35 pm - 6:45 pm | Discussion |
6:45 pm - 7:10 pm | David Ecker (Ibis Biosciences (Abbott), USA) "Solutions to Enrolling the Right Patients: Portable Diagnostics" |
7:10 pm - 7:20 pm | Discussion |
7:20 pm - 7:50 pm | Debra Goff (Ohio State University Wexner Medical Center, USA) "From the Frontline: How Clinicians Apply New Diagnostics Tests" |
7:50 pm - 8:00 pm | Discussion |
8:00 pm | Dinner |
Friday |
7:30 am - 8:30 am | Breakfast |
9:00 am | Departure |